# P36502 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *blaZ* gene (UniProt P36502) encodes a class A serine β-lactamase in *Staphylococcus aureus*, primarily conferring resistance to penicillins by hydrolyzing the β-lactam ring.
- This gene is frequently located on mobile plasmids or integrated into the staphylococcal cassette chromosome (SCCmec), facilitating horizontal gene transfer and rapid dissemination of antibiotic resistance.
- Expression of *blaZ* is tightly regulated by the BlaR1 sensor-transducer and BlaI repressor system, which induces β-lactamase production in response to β-lactam antibiotics.
- BlaZ is a critical determinant of penicillin resistance in staphylococci, complicating antibiotic therapy and necessitating the use of β-lactamase-stable antibiotics or co-administration with β-lactamase inhibitors like clavulanic acid, sulbactam, or tazobactam.
- Structural analysis reveals BlaZ as a prototypical class A β-lactamase with a conserved active site featuring the SXXK motif, responsible for its enzymatic activity and susceptibility to mechanism-based inhibitors.
- Clinical detection of *blaZ* relies on phenotypic tests like the nitrocefin assay and genotypic methods such as PCR, guiding therapeutic choices to overcome resistance.

---

## Executive Summary & Key Metadata

The UniProt accession **P36502** corresponds to the **BlaZ** (PC1) **β-lactamase** precursor from *Staphylococcus aureus*, a prototypical class A serine β-lactamase that confers resistance to penicillin and related β-lactam antibiotics. This gene product is a quintessential model for understanding enzymatic antibiotic resistance, structural enzymology of the β-lactamase superfamily, and the molecular evolution of clinically significant antimicrobial resistance (AMR) determinants. The protein is a secreted, monomeric enzyme that hydrolyzes the β-lactam ring of penicillins, rendering them inactive. Its clinical significance is profound, as it is the primary mechanism of penicillin resistance in staphylococci, a problem that has driven the development of β-lactamase-stable antibiotics and β-lactamase inhibitors.

| **Metadata Field** | **Value** |
| :--- | :--- |
| **HGNC Symbol** | Not applicable (bacterial gene); commonly referred to as *blaZ* |
| **UniProt Accession** | P36502 |
| **Representative PDB ID** | True (e.g., 3BLM, 1BLC, 2BLM) |
| **Chromosomal Locus** | Typically plasmid-borne (e.g., pI258, pT181 family) or chromosomal on the staphylococcal cassette chromosome (SCCmec) in some isolates; not a fixed chromosomal locus |
| **Primary Molecular Function** | Serine-type β-lactamase activity (EC 3.5.2.6); hydrolysis of β-lactam antibiotics, primarily penicillins |
| **Disease & Pathology Associations** | Penicillin resistance in *S. aureus*; contributes to methicillin-resistant *S. aureus* (MRSA) phenotype when co-expressed with mecA; complicates antibiotic therapy |

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Genetic Context and Mobility

The *blaZ* gene is not a static chromosomal element. It is most frequently located on **transmissible plasmids** (e.g., pI258, pI524, pT181) and, in some lineages, integrated into the *S. aureus* chromosome as part of a larger mobile genetic element. The gene is typically part of a conserved operon that includes the *blaZ* gene itself, a divergently transcribed *blaR1* gene encoding a signal-transducing sensor-transducer, and a *blaI* gene encoding a repressor protein. This tripartite regulatory system is the canonical model for inducible β-lactamase expression.

The plasmid-borne nature of *blaZ* has profound implications for its dissemination. Conjugative and mobilizable plasmids facilitate horizontal gene transfer (HGT) between staphylococcal species and genera, enabling the rapid spread of resistance determinants across clinical settings. The genetic context of *blaZ* is often flanked by insertion sequences (IS) and transposons, which further promote its mobility and recombination.

### 1.2 Promoter Architecture and Regulatory Elements

The *blaZ* promoter region is tightly regulated. The **BlaI** repressor binds to two operator sequences (OP1 and OP2) that overlap the *blaZ* promoter and the *blaR1* promoter, respectively. This dual-operator binding creates a DNA loop that effectively silences both genes. The promoter itself contains a canonical -10 (TATAAT) and -35 (TTGACA) box recognized by the σ^A factor of *S. aureus*.

Induction occurs when extracellular β-lactam antibiotics bind to the extracellular sensor domain of **BlaR1**, a transmembrane zinc-dependent metalloprotease. This binding triggers autocatalytic cleavage of BlaR1's cytoplasmic domain, which then acts as a protease to cleave BlaI. Cleavage of BlaI relieves the repression of *blaZ*, leading to rapid transcription and translation of the β-lactamase. This signal transduction cascade is a sophisticated example of bacterial environmental sensing and gene regulation.

### 1.3 Transcriptional Regulation and mRNA Stability

Transcription of *blaZ* is inducible and tightly controlled. The *blaZ* mRNA is relatively stable, allowing for sustained production of the enzyme during antibiotic challenge. The 5' untranslated region (UTR) of the *blaZ* mRNA contains a **ribosome binding site (RBS)** that is accessible for efficient translation initiation. No alternative splicing occurs, as this is a prokaryotic gene; however, the protein is synthesized as a **preproprotein** with an N-terminal signal peptide.

### 1.4 Isoforms and Post-Translational Processing

While *blaZ* does not produce splice isoforms, it undergoes critical post-translational processing. The nascent polypeptide (prepro-BlaZ) contains a 28-amino acid N-terminal signal peptide that directs the protein to the Sec-dependent secretion pathway. Upon translocation across the cytoplasmic membrane, the signal peptide is cleaved by signal peptidase I, yielding the mature, enzymatically active β-lactamase. The mature protein is then released into the periplasmic space (in Gram-negatives) or the extracellular milieu (in Gram-positives). A minor fraction may remain cell-wall associated.

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Fold and Structural Classification

BlaZ is the archetypal member of the **class A β-lactamase** family (Ambler classification), which shares structural homology with penicillin-binding proteins (PBPs). The mature enzyme is a compact, globular, monomeric protein of approximately 257 amino acids (molecular weight ~29 kDa). Its structure is dominated by two distinct domains:

1.  **All-α Domain:** Composed of a bundle of α-helices (helices H1, H2, H3, H4, H8, H9, H10, H11).
2.  **α/β Domain:** A five-stranded antiparallel β-sheet (β1-β5) flanked by α-helices (H5, H6, H7).

The active site is located in a deep groove at the interface between these two domains. This groove is lined by conserved motifs that are the hallmark of class A β-lactamases.

### 2.2 Active Site Architecture and Catalytic Machinery

The catalytic machinery of BlaZ is centered on a **serine nucleophile** (Ser70, using the standard class A numbering scheme based on the TEM-1 enzyme). The key catalytic residues and motifs are:

- **SXXK Motif (Ser70-Xaa-Xaa-Lys73):** This tetrad is located at the N-terminus of helix H2. Ser70 is the catalytic nucleophile that attacks the carbonyl carbon of the β-lactam ring. Lys73 acts as a general base, abstracting a proton from Ser70 to activate it for nucleophilic attack.
- **SDN Loop (Ser130-Asp131-Asn132):** This loop connects helix H3 and strand β3. Ser130 and Asn132 are critical for positioning the water molecule involved in deacylation and for stabilizing the tetrahedral transition state.
- **KTG Motif (Lys234-Thr235-Gly236):** Located on strand β4, this motif forms the "back wall" of the active site. Lys234 interacts with the carboxylate group of the β-lactam substrate, anchoring it in the correct orientation.
- **Ω-Loop (Glu166-Xaa-Xaa-Xaa-Xaa-Asn170):** This loop is a conserved structural element that forms one wall of the active site. Glu166 is the general base that activates the deacylating water molecule, while Asn170 stabilizes the oxyanion hole.

The catalytic mechanism proceeds via a two-step acylation-deacylation pathway:

1.  **Acylation:** Ser70 attacks the β-lactam carbonyl carbon, forming a tetrahedral oxyanion intermediate stabilized by the oxyanion hole (backbone amides of Ser70 and Gln237). This intermediate collapses to form a covalent acyl-enzyme intermediate, with the β-lactam ring opened.
2.  **Deacylation:** A water molecule, activated by Glu166, attacks the acyl-enzyme intermediate, leading to the formation of a second tetrahedral intermediate. This collapses to release the hydrolyzed, inactive antibiotic and regenerate the free enzyme.

### 2.3 Substrate Specificity and Extended Spectrum

BlaZ is a **penicillinase**, meaning it efficiently hydrolyzes penicillins (e.g., penicillin G, ampicillin) but has poor activity against cephalosporins, carbapenems, and monobactams. This narrow substrate profile is dictated by the size and flexibility of the active site. The R1 side chain of the β-lactam substrate fits into a specific binding pocket; bulky side chains (as in cephalosporins) are sterically hindered. However, mutations in the Ω-loop and other active site residues can expand the substrate profile, leading to "extended-spectrum" β-lactamases (ESBLs), although this is less common in BlaZ than in TEM and SHV enzymes.

### 2.4 Structural Dynamics and Inhibitor Binding

The Ω-loop and the B3 β-strand exhibit significant conformational flexibility, which is essential for substrate binding and catalysis. This flexibility also explains the mechanism of action of **clavulanic acid**, a mechanism-based "suicide" inhibitor. Clavulanate initially binds to the active site and undergoes acylation. However, the resulting acyl-enzyme intermediate is processed to form a stable, inactive cross-linked species, effectively trapping the enzyme in a dead-end complex. This structural insight has been crucial for the rational design of newer β-lactamase inhibitors.

> **Interactive 3D Protein Visualizer: Load P36502 (PDB: true)**
> [Launch the interactive 3D protein structure viewer for P36502](/tools/protein-structure-viewer?source=alphafold&accession=P36502)
> *This tool allows you to explore the atomic coordinates, highlight the catalytic SXXK motif, visualize the Ω-loop, and measure distances between key active-site residues.*

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The BlaR1-BlaI-BlaZ Signal Transduction System

The primary "signaling pathway" associated with P36502 is not a eukaryotic cascade but a sophisticated bacterial two-component-like system that regulates its own expression. This system is a model for understanding how bacteria sense and respond to cell-wall stress.

```mermaid
sequenceDiagram
    participant Ext as "Extracellular Space"
    participant BlaR1 as "BlaR1 (Sensor/Transducer)"
    participant Mem as "Cytoplasmic Membrane"
    participant BlaI as "BlaI (Repressor)"
    participant blaZ as "blaZ Gene"
    participant BlaZ as "BlaZ (β-lactamase)"
    Ext->>BlaR1: β-lactam antibiotic binds to sensor domain
    Note over BlaR1: Conformational change & autocatalytic cleavage of cytoplasmic domain
    BlaR1->>Mem: Activated cytoplasmic protease domain
    Mem->>BlaI: Cleaves BlaI repressor dimer
    BlaI-->>blaZ: Dissociation from operator sites (OP1/OP2)
    blaZ->>BlaZ: Transcription & translation of β-lactamase
    BlaZ->>Ext: Secretion of mature enzyme
    BlaZ->>Ext: Hydrolysis of β-lactam ring (inactivation)
```

### 3.2 Molecular Mechanism of Induction

1.  **Sensing:** The extracellular domain of BlaR1 contains a β-lactam binding pocket. When a β-lactam antibiotic (e.g., penicillin) binds, it forms a covalent adduct with the active-site serine of BlaR1's sensor domain.
2.  **Signal Transduction:** This acylation event triggers a conformational change that is transmitted across the membrane to the cytoplasmic domain. The cytoplasmic domain of BlaR1 is a zinc-dependent metalloprotease. The conformational change activates its protease function, leading to autocatalytic cleavage of the BlaR1 cytoplasmic domain.
3.  **Repressor Inactivation:** The activated BlaR1 protease then cleaves the BlaI repressor at specific sites. BlaI is a homodimer that binds to the operator sequences. Cleavage of BlaI inactivates it, causing it to dissociate from the DNA.
4.  **Derepression:** With BlaI removed, RNA polymerase can access the *blaZ* promoter, leading to high-level expression of the β-lactamase.

### 3.3 Protein-Protein Interaction Networks

The key protein-protein interactions in this system are:

- **BlaR1-BlaI:** The direct proteolytic interaction between the activated BlaR1 protease and the BlaI repressor. This is a transient but highly specific interaction.
- **BlaI-DNA:** The binding of the BlaI dimer to the operator sequences (OP1 and OP2). This is a high-affinity interaction that is disrupted upon BlaI cleavage.
- **BlaZ-β-lactam:** The enzyme-substrate interaction that is the core of the resistance mechanism.

### 3.4 Cross-Talk with Other Resistance Mechanisms

The *blaZ* system does not operate in isolation. In clinical isolates, *blaZ* is often found alongside *mecA*, the gene encoding the alternative PBP2a that confers methicillin resistance. The expression of *mecA* is regulated by the homologous *mecI-mecR1* system. There is significant cross-talk between the *bla* and *mec* regulatory systems. The BlaR1-BlaI system can regulate *mecA* expression, and vice-versa, contributing to the complex, heterogeneous expression of resistance phenotypes seen in MRSA. This cross-talk is clinically relevant because β-lactamase inhibitors that target BlaZ can also affect the regulation of PBP2a.

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Naturally Occurring Variants

BlaZ is not a human gene, so "pathogenic mutations" in the classical sense do not apply. However, mutations that alter its activity, substrate profile, or inhibitor susceptibility are of immense clinical importance. These are not germline mutations but rather **acquired, adaptive mutations** selected under antibiotic pressure.

### 4.2 Mutations Affecting Catalytic Activity and Substrate Profile

- **Ω-loop Mutations (e.g., Glu166Lys, Asp179Asn):** These mutations can alter the conformation of the active site, potentially expanding the substrate profile to include cephalosporins. They may also affect the stability of the acyl-enzyme intermediate, leading to increased or decreased catalytic efficiency.
- **Active Site Pocket Mutations (e.g., Ser130Gly, Arg244Ser):** These can alter the positioning of the substrate or the deacylating water molecule. For example, mutations at Arg244, which forms a salt bridge with the carboxylate of the substrate, can reduce the affinity for β-lactams but also affect inhibitor binding.
- **Promoter/Operator Mutations:** Mutations in the *blaZ* promoter or the *blaI* operator sites can lead to **constitutive overproduction** of the β-lactamase. This is a common mechanism of high-level penicillin resistance, as the sheer amount of enzyme can overwhelm the inhibitor or the antibiotic.

### 4.3 Inhibitor-Resistant (IRT) and Extended-Spectrum (ESBL) Variants

While less common than in TEM/SHV β-lactamases, mutations in BlaZ can confer resistance to clinically used β-lactamase inhibitors (e.g., clavulanic acid). These are often referred to as **inhibitor-resistant TEM (IRT)**-like variants. The mutations typically occur in the Ω-loop or near the oxyanion hole, disrupting the stable binding of the inhibitor.

### 4.4 Clinical Phenotypes and Diagnostics

The clinical phenotype associated with *blaZ* is **penicillin resistance** in staphylococci. In the clinical microbiology laboratory, this is detected by:

- **Phenotypic Testing:** Disk diffusion or broth microdilution with penicillin. A positive nitrocefin test confirms β-lactamase production.
- **Genotypic Testing:** PCR amplification of the *blaZ* gene or DNA hybridization assays.

The clinical differential for a *blaZ*-positive *S. aureus* isolate includes:

- **Penicillin-Susceptible *S. aureus* (PSSA):** Lacks *blaZ*.
- **Methicillin-Resistant *S. aureus* (MRSA):** Carries *mecA*; often also carries *blaZ*. The presence of *blaZ* can complicate treatment, as these isolates are resistant to all β-lactams.
- **Methicillin-Susceptible *S. aureus* (MSSA) with *blaZ*:** Resistant to penicillin but susceptible to β-lactamase-stable penicillins (e.g., oxacillin, cefazolin).

## 5. Host-Pathogen & Viral Interactions (If applicable)

### 5.1 Role in *Staphylococcus aureus* Pathogenesis

BlaZ is not a classical virulence factor like toxins or adhesins. However, it is a critical **fitness factor** that enables *S. aureus* to survive and proliferate in the host during β-lactam antibiotic therapy. By inactivating the antibiotic, BlaZ allows the bacterium to establish and maintain infection, leading to prolonged disease, increased bacterial burden, and enhanced transmission.

### 5.2 Interaction with the Host Immune System

The β-lactamase itself does not directly interact with host immune cells. However, the cell-wall fragments released during β-lactam-induced lysis (in susceptible bacteria) are potent immunostimulatory molecules. In a *blaZ*-positive strain, the cell wall remains intact, and the bacterium is not lysed, thus avoiding the release of these pro-inflammatory fragments. This is an indirect mechanism by which BlaZ modulates the host immune response.

### 5.3 Interactions with Bacteriophages

Bacteriophages can transduce the *blaZ* gene between staphylococcal strains. This is a significant mechanism of horizontal gene transfer in the clinical setting. Phage-mediated transduction can transfer *blaZ* from a resistant donor to a susceptible recipient, rapidly spreading resistance within a bacterial population. The *blaZ* gene is often located on transposons (e.g., Tn552) that can integrate into the chromosome or plasmids, facilitating phage-mediated mobilization.

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 BlaZ as a Drug Target

BlaZ is a validated and clinically significant drug target. The goal of targeting BlaZ is not to kill the bacterium directly but to **inactivate the resistance mechanism**, thereby restoring the activity of β-lactam antibiotics.

### 6.2 FDA-Approved β-Lactamase Inhibitors

The following mechanism-based inhibitors are FDA-approved and are used in combination with β-lactam antibiotics to overcome *blaZ*-mediated resistance:

- **Clavulanic Acid:** A naturally occurring "suicide" inhibitor. It is formulated with amoxicillin (Augmentin) and ticarcillin (Timentin). It is a potent inhibitor of BlaZ.
- **Sulbactam:** A synthetic sulfone inhibitor. It is formulated with ampicillin (Unasyn) and cefoperazone. It is a weaker inhibitor of BlaZ than clavulanic acid but is still clinically effective.
- **Tazobactam:** A synthetic sulfone inhibitor, structurally related to sulbactam. It is formulated with piperacillin (Zosyn) and ceftolozane (Zerbaxa). It is a potent inhibitor of class A β-lactamases, including BlaZ.

### 6.3 Investigational and Next-Generation Inhibitors

- **Avibactam:** A non-β-lactam diazabicyclooctane (DBO) inhibitor. It is a covalent, reversible inhibitor that is highly potent against class A and class C β-lactamases. It is formulated with ceftazidime (Avycaz). While primarily developed for ESBLs and KPCs, it also inhibits BlaZ.
- **Vaborbactam:** A cyclic boronate inhibitor. It is formulated with meropenem (Vabomere). It is a potent inhibitor of class A and C β-lactamases.
- **Relebactam:** A DBO inhibitor, similar to avibactam. It is formulated with imipenem and cilastatin (Recarbrio).

### 6.4 Pharmacogenomic Considerations

In the context of bacterial infections, "pharmacogenomics" refers to the genetic determinants of the bacterium that influence drug efficacy. The presence of *blaZ* is a key pharmacogenomic marker. The choice of antibiotic therapy is guided by the resistance genotype of the infecting strain. For example, a *blaZ*-positive MSSA infection should be treated with a β-lactamase-stable penicillin (e.g., oxacillin) or a β-lactam/β-lactamase inhibitor combination, not with penicillin alone.

## 7. Bioinformatic Resources & Database Accessions

The following table provides key database accessions and resources for the P36502 gene and protein.

| **Database** | **Accession / Identifier** | **Description** |
| :--- | :--- | :--- |
| **UniProt** | [P36502](https://www.uniprot.org/uniprotkb/P36502/entry) | Primary protein sequence, function, and annotation. |
| **RCSB PDB** | [3BLM](https://www.rcsb.org/structure/3BLM), [1BLC](https://www.rcsb.org/structure/1BLC), [2BLM](https://www.rcsb.org/structure/2BLM) | Experimentally determined 3D structures of BlaZ (PC1). |
| **NCBI Gene** | [2807885](https://www.ncbi.nlm.nih.gov/gene/2807885) | Gene information for *blaZ* from *S. aureus*. |
| **NCBI Protein** | [AAA26633.1](https://www.ncbi.nlm.nih.gov/protein/AAA26633.1) | Protein sequence record. |
| **InterPro** | [IPR000871](https://www.ebi.ac.uk/interpro/entry/InterPro/IPR000871/) | Beta-lactamase/transpeptidase-like domain. |
| **CDD (NCBI)** | [cd00225](https://www.ncbi.nlm.nih.gov/Structure/cdd/cd00225) | Conserved Domain Database entry for beta-lactamases. |
| **Gene Ontology (GO)** | GO:0008800 (beta-lactamase activity), GO:0046679 (response to antibiotic) | Functional annotations. |
| **STRING** | [P36502](https://string-db.org/network/P36502) | Protein-protein interaction network (predicts interactions with BlaR1, BlaI). |
| **BioCyc** | [G0O-2341](https://biocyc.org/gene?orgid=STAAW&id=G0O-2341) | Metabolic pathway database entry. |
| **CARD (Comprehensive Antibiotic Resistance Database)** | [ARO:3000149](https://card.mcmaster.ca/ontology/3000149) | Antibiotic resistance ontology entry for BlaZ. |

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1.  Ambler, R. P. (1980). The structure of beta-lactamases. *Philosophical Transactions of the Royal Society of London. B, Biological Sciences*, 289(1036), 321-331. [https://doi.org/10.1098/rstb.1980.0049](https://doi.org/10.1098/rstb.1980.0049)
2.  Bush, K., & Jacoby, G. A. (2010). Updated functional classification of beta-lactamases. *Antimicrobial Agents and Chemotherapy*, 54(3), 969-976. [https://doi.org/10.1128/AAC.01009-09](https://doi.org/10.1128/AAC.01009-09)
3.  Fuda, C., Suvorov, M., Vakulenko, S. B., & Mobashery, S. (2004). The basis for resistance to beta-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. *Journal of Biological Chemistry*, 279(39), 40802-40806. [https://doi.org/10.1074/jbc.M403589200](https://doi.org/10.1074/jbc.M403589200)
4.  Hackbarth, C. J., & Chambers, H. F. (1993). blaI and blaR1 regulate beta-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus. *Antimicrobial Agents and Chemotherapy*, 37(5), 1144-1149. [https://doi.org/10.1128/AAC.37.5.1144](https://doi.org/10.1128/AAC.37.5.1144)
5.  Herzberg, O., & Moult, J. (1987). Bacterial resistance to beta-lactam antibiotics: crystal structure of beta-lactamase from Staphylococcus aureus PC1 at 2.5 A resolution. *Science*, 236(4802), 694-701. [https://doi.org/10.1126/science.3107125](https://doi.org/10.1126/science.3107125)
6.  Jelsch, C., Mourey, L., Masson, J. M., & Samama, J. P. (1993). Crystal structure of Escherichia coli TEM1 beta-lactamase at 1.8 A resolution. *Proteins: Structure, Function, and Genetics*, 16(4), 364-383. [https://doi.org/10.1002/prot.340160406](https://doi.org/10.1002/prot.340160406)
7.  Kernodle, D. S., & McGraw, P. A. (1994). The blaZ gene of Staphylococcus aureus encodes a beta-lactamase that is a major determinant of resistance to penicillins. *Antimicrobial Agents and Chemotherapy*, 38(10), 2385-2390. [https://doi.org/10.1128/AAC.38.10.2385](https://doi.org/10.1128/AAC.38.10.2385)
8.  Lowther, W. T., & Matthews, B. W. (2002). Metalloaminopeptidases: common functional themes in disparate structural surroundings. *Chemical Reviews*, 102(12), 4581-4608. [https://doi.org/10.1021/cr0101757](https://doi.org/10.1021/cr0101757)
9.  Massova, I., & Mobashery, S. (1998). Kinship and diversification of bacterial penicillin-binding proteins and beta-lactamases. *Antimicrobial Agents and Chemotherapy*, 42(1), 1-17. [https://doi.org/10.1128/AAC.42.1.1](https://doi.org/10.1128/AAC.42.1.1)
10. Medeiros, A. A. (1997). Evolution and dissemination of beta-lactamases accelerated by generations of beta-lactam antibiotics. *Clinical Infectious Diseases*, 24(Supplement_1), S19-S45. [https://doi.org/10.1093/clinids/24.Supplement_1.S19](https://doi.org/10.1093/clinids/24.Supplement_1.S19)
11. Peitsaro, N., Polianskyte, Z., Tuimala, J., Pörn-Ares, I., Liobikas, J., Speer, O., ... & Eriksson, O. (2008). Evolution of a family of metazoan active-site-serine enzymes from a common ancestor: a model for the evolution of the beta-lactamase superfamily. *BMC Evolutionary Biology*, 8(1), 26. [https://doi.org/10.1186/1471-2148-8-26](https://doi.org/10.1186/1471-2148-8-26)
12. Rowland, S. J., & Dyke, K. G. (1990). Tn552, a novel transposable element from Staphylococcus aureus. *Molecular Microbiology*, 4(6), 961-975. [https://doi.org/10.1111/j.1365-2958.1990.tb00667.x](https://doi.org/10.1111/j.1365-2958.1990.tb00667.x)
13. Wang, F., Cassidy, C., & Sacchettini, J. C. (2006). Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase. *Journal of Biological Chemistry*, 281(28), 19643-19651. [https://doi.org/10.1074/jbc.M601596200](https://doi.org/10.1074/jbc.M601596200)
14. Zhang, H. Z., Hackbarth, C. J., Chansky, K. M., & Chambers, H. F. (2001). A proteolytic transmembrane signaling pathway and resistance to beta-lactams in staphylococci. *Science*, 291(5510), 1962-1965. [https://doi.org/10.1126/science.1055144](https://doi.org/10.1126/science.1055144)